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S U M M A R Y
Objectives: Fibrin has been demonstrated to function protectively against pathogens in our previous
studies, but we observed that a very high level of ﬁbrin played a negative role during infection. We
performed this research to address the complication.
Methods: After infection, mice were monitored daily and harvested on day 4. The ﬁbrin levels within the
tissue samples were quantiﬁed by Western-blot. The in situ assay was used to detect plasminogen
activators, protein C-ase and prothrombinase activation. PT-PCR was used to test coagulation factors
expression.
Results: Mice treated with Coumadin showed that the protection correlates with ﬁbrin levels. By
interacting with Toll-like receptor 4, the hexa-acylated lipopolysaccharide, although not the tetra-
acylated lipopolysaccharide, activates coagulation and regulates plasminogen activator inhibitor 1,
thrombin activatable ﬁbrinolysis inhibitor and thrombomodulin expression through myeloid
differentiation factor 88, leading to plasminogen activators, protein C-ase and prothrombinase
activation and ﬁbrin formation. Because of the regulation, ﬁbrin formation was controlled to deposit
appropriate levels and confer protection.
Conclusions: We demonstrated that the appropriate level of ﬁbrin formation was deployed by hexa-
acylated LPS-lipid A through myeloid differentiation factor 88 to confer protection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Plague, including bubonic plague, pneumonic plague and
septicemic plague, is caused by Yersinia pestis (Y. pestis), which
is predominantly an extracellular pathogen. Pneumonic plague is
transmitted easily, progresses rapidly, and causes high mortality.
Because it spreads from person to person via infectious respiratory
droplets,1 with some strains acquiring anti-biotic resistance,2,3
plague has been weaponized.4,5 As one of the most deadly
infectious diseases in the world, plague frequently leads to sepsis
and coagulopathy.6,7 A better understanding of the coagulant* Corresponding author. Department of Immunology, State Key Laboratory of
Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology.
Tel.: +86-10-66948679; fax: +86-10-66948678.
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http://dx.doi.org/10.1016/j.ijid.2015.01.021
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).aspects of sepsis has contributed to rational therapeutic plans for
several important diseases,8,9 including plague. Fibrin, the ﬁnal
product of the coagulation cascade, is an important means of
immune control for a variety of pathogens.10–12 In mouse models,
gene-targeted ﬁbrin-deﬁciency increases lethality in cases in
which Y. pestis bacilli are inoculated subcutaneously to mimic
bubonic plague. Based on these studies, we predicted that ﬁbrin
could confer protection by restricting the ability of bacteria to
escape the respiratory system or by facilitating immunity.
Nevertheless, previous studies found that a very high level of
ﬁbrin resulted in earlier death in animals.13 Base on this
complication, we designed a series of illustrative experiments.
We hypothesize that ﬁbrin is protective; however, based on the
data in this study, the protection depends on the level of
deposition. In our study, two bacteria strains (KIM D27 and KIM
D27-pLpxL) were used. KIM D27, a Pgm-deﬁcient strain, is
conditionally attenuated in mice when administered subcutane-
ously; infection is induced at very low doses with intranasalciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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local inﬂammation, including a complex type III secretion system
(T3SS),16 low-calcium response V antigen (LcrV) and several
Yersinia outer membrane proteins (Yops).17,18 At 37 8C, Y. pestis
produces tetra-acylated lipopolysaccharide (LPS)-lipid A,19,20
which is an immunity suppressor with low stimulatory activity
for the immune system.19,21,22 In contrast to KIM D27, Yersinia KIM
D27-pLpxL, which was modiﬁed by introducing a plasmid
encoding acyltransferase, produces hexa-acylated LPS-lipid A at
26 8C (ﬂea temperature) and 37 8C, a potent Toll-like receptor 4
(TLR4) stimulating to initiate innate responses (host tempera-
ture).23,24 Y. pestis provides an excellent model for testing the
relationship between coagulopathy and immunity. Lien suggested
that Yersinia KIM D27-pLpxL was a potential vaccine candidate
based on stimulation of innate immunity.23 In our study, another
component of gram-negative bacteria, hexa-acylated LPS, was
employed for this study to evaluate the complicated roles of ﬁbrin
deposition during infection.
We demonstrated that the appropriate level of ﬁbrin forma-
tion was deployed by hexa-acylated LPS-lipid A through myeloid
differentiation factor 88 (MyD88) to confer protection. An
appropriate ﬁbrin level performs critical protective roles during
defense against plague, revealing the ‘‘double-edged sword’’
characteristic of ﬁbrin during infections. Our data emphasized
the outstanding essential function of ﬁbrin formation in
protection against pneumonic plague, which correlated strictly
with the ﬁbrin levels. The work in this study aimed to augment
our understanding of the roles of vaccine candidates in deploying
ﬁbrin formation.
2. Materials and Methods
2.1. Mice
C57BL/6 mice and MyD88 gene deﬁcient mice (MyD88 KO)
(backcrossed seven generations to C57BL/6 mice) were purchased
from Jackson lab (BarHarbor, ME) and housed in a speciﬁc
pathogen-free facility. Where indicated, mice were anticoagulated
pharmacologically by supplementing drinking water with differ-
ent doses (2 mg/L, 1 mg/L, 0.5 mg/L, 0.25 mg/L, 0.125 mg/L,
0.0625 mg/L and none) of coumadin [3-(a-acetonylbenzyl)-4-
hydroxycoumarin; Sigma] beginning 3 days prior to infection or
1 day after infection with replenishment every 48 hours; This
anticoagulant regimen reduces ﬁbrin deposition in mice during
infection. The animal experiments were reviewed and approved by
the Yuhuangding Hospital of PLA and Beijing Institute of
Microbiology and Epidemiology Animal Care and Use Committee.
2.2. Bacteria and Infection
Y. pestis strain KIM D27, a pigmentation-negative strain, was
obtained from bacterial seeds room in Yuhuangding Hospital. The
pigmentation-negative phenotype results from a 102-kb chromo-
somal deletion that partially attenuates Y. pestis, particularly when
administered intranasally: the medial lethal dose was approxi-
mately 1104 CFU when administered intranasally, as calculated
by the method of Reed and Muench.
Y. pestis KIM D27-pLpxL was prepared by transforming strain
D27 with plasmid pLpxL in our lab; the median lethal dose was
greater than 1107 CFU when administered via the intranasal
route.
KIM D27 and KIM D27-pLpxL were regrown overnight with
continuous shaking in Bacto heart infusion broth supplemented
with 2.5 mM CaCl2 and then diluted to an OD of approximately
0.1 and regrown for 3 h at 26 8C, washed with saline, quantiﬁed by
measuring the optical density at 620 nm, and applied in a volumeof 30 ml of saline to the nares of mice lightly anesthetized with
isoﬂurane. The number of bacteria in the inoculating dose was
conﬁrmed by plating. The intranasal infection doses of KIM D27
and KIM D27-pLpxL were 2105 CFU and 2106 CFU, respectively.
2.3. Survival and bacterial burden
After infection, mice were monitored daily, Unresponsive
recumbent animals were considered moribund and were euthan-
atized.
At the indicated days after initiating infection, mice received
500U heparin intravenously just prior to euthanasia by carbon
dioxide narcosis. The numbers of viable bacteria in lungs, spleens
and livers were measured by homogenizing tissues in saline and
then counting CFU after plating on BHI agar.
2.4. Fibrin deposition test
The ﬁbrin levels within the tissue samples were quantiﬁed as
described by Smiley’s lab.10 In brief, insoluble ﬁbrin was extracted
from homogenized tissue and quantiﬁed by Western blot using
biotinylated ﬁbrin-speciﬁc mAb 350 (American Diagnostica)
followed by rabbit anti-biotin (Bethyl Laboratories), anti-rabbit
HRP polymer (DakoCytomation), and chemiluminescent detection
(Bio-Rad). Standard curves were generated by treating puriﬁed
mouse ﬁbrinogen (Sigma-Aldrich) with human thrombin (Enzyme
Research Laboratories).
2.5. In situ assays
All in site assays are designed by Smiley’s lab.25 prothrombinase
(PTase) activity: fresh frozen livers were sectioned (7 mm)
mounted onto slides, and overlaid with human prothrombin
(Enzyme Research Laboratories). After incubation at 37 8C,
thrombin levels were quantiﬁed using Spectrozyme TH (American
Diagnostica) and normalized to the area of the tissue section.
Puriﬁed human alpha-thrombin (Enzyme Research Laboratories)
was used as standard. Protein C-ase (PCase) and plasminogen
activators (PA) activity assays were performed similarly to PTase
assays, with some modiﬁcations. PTase, PCase and PA activity are
presented as fold-change relative to the levels measured in tissue
samples collected from naı¨ve mice.
2.6. Real-time PCR
The tissue level of the mRNA encoding thrombomodulin (TM),
plasminogen activator inhibitor 1 (PAI-1), and thrombin activa-
table ﬁbrinolysis inhibitor (TAFI) were measured using real-time
PCR (PerkinElmer); the values were normalized to level of mRNA
encoding GAPDH and expressed as the fold change relative to the
level in uninfected wild type mice.25
Real-time PCR primer and probe sequences for PAI-1, TAFI, TF
and TM are as follows; PAI1 forward GAGCCAATCACAAGGCACCT,
PAI1 reverse TCCCAGAGACCAGAACCAGG, PAI1 probe TCAGGATG-
CAGATGTCTTCAGCCCTTG. TAFI forward TTCGAGAAGTACCCACTT-
TATGTT, TAFI reverse CCATTCTCTGGCATGGATT, TAFI probe
AATGCCATCTGGATCGACTGTGG. TM forward TGTATGTGGTCCT-
GCCTCAA, TM reverse CGAAGCACACAACTCATGCT, TM probe
TCAGAGCCTGACAGATGGAAGCACC.
2.7. Histology
Tissue samples were ﬁxed in 10% neutral buffered formalin,
embedded in parafﬁn, sectioned, and stained with hematoxylin
and eosin. Representative photomicrographs are presented at a
magniﬁcation of 200.
Q. Zhao et al. / International Journal of Infectious Diseases 33 (2015) 142–1481442.8. Statistics
The statistical analyses were performed using Prism 5.0 soft-
ware (GraphPad Software, Inc.). The survival data were analyzed by
a log rank test. The CFU data were analyzed using parametric tests
(Student’s t-test or one-way analysis of variance, as indicated).
3. Results
3.1. An appropriate level of ﬁbrin is protective
Our previous studies demonstrated that ﬁbrin conferred
protection against broad infections; however, occasionally, very
high levels of ﬁbrin caused infected animals to die sooner.13 Based
on this complication, we designed a series of experiments to
further evaluate the effect of ﬁbrin. C57BL/6 mice were treated
with different doses of Coumadin in drinking water, infected
intranasally with 2105 CFU KIM D27 and monitored for survival.
The mice treated with the highest dose of Coumadin (2 mg/L) and
the mice treated with no Coumadin succumbed to infection sooner
than the mice treated with a moderate dose of Coumadin
(0.5 mg/L) (Figure 1A, p<0.05). On day 4 after inoculation, the
mice were sacriﬁced, and the ﬁbrin deposition in the livers was
observed. We detected a moderate level of ﬁbrin in the mice
treated with 0.5 mg/L of Coumadin compared with the miceFigure 1. The appropriate level of ﬁbrin protects against pneumonic plague in
naı¨ve mice
C57BL/6 mice were treated with different doses of Coumadin in drinking water
(2 mg/L, 1 mg/L, 0.5 mg/L, 0.25 mg/L, 0.125 mg/L, 0.0625 mg/L, none). The data are
shown for the mice treated with 2 mg/L, 0.5 mg/L, or none, infected with 2105 CFU
KIMD27 and monitored for survival. The mice treated with the highest dose of
Coumadin or with no Coumadin succumbed to infection sooner than the mice
treated with a moderate dose of Coumadin (A, p=0.03, 5 mice per group). On day
4 after inoculation, the mice were sacriﬁced and the ﬁbrin deposition in the livers
was observed. We detected moderate ﬁbrin levels in the mice treated with 0.5 mg/L
Coumadin (B, p<0.0001, 5 mice per group). Results similar to those shown in
Figure 2 were observed in two independent experiments. The data were analyzed
by one way analysis of variance.treated with other doses (Figure 1B, p<0.0001). We hypothesized
that ﬁbrin confers protection only at the appropriate level. To
conﬁrm this result and to investigate the detailed mechanism, the
modiﬁed bacterial strain, KIM D27/pLpxL, which could produce
hexa-acylated LPS-lipid A, was used in this study. The C57BL/6
mice were i.n. inoculated with 2105 CFU KIM D27 and 2106 CFU.
On days 1, 2, 3, 4, 7, and 10 after inoculation, the mice were
sacriﬁced, and the CFU and ﬁbrin deposition in the liver was
observed. Initially, the ﬁbrin levels in the mice infected with KIM
D27/pLpxL were higher, and the levels were lower after day 3 than
the ﬁbrin levels in the mice infected with KIM D27. The ﬁbrin
maintained nearly the identical level after day 3 during KIM
D27/pLpxL infection; however, the ﬁbrin level continued to
increase in KIM D27 infection (Figure 2A, similar result was
shown by Smiley lab, Figure 7B26). With this high level of ﬁbrin, the
mice infected with a lower dose of KIM D27 died sooner than the
mice infected with KIM D27/pLpxL (Figure 2B).
3.2. Hexa-acylated LPS-lipid A regulates coagulation factors through
MyD88
In the previous study, we treated mice with Coumadin to
regulate ﬁbrin formation, suggesting an investigation of how theFigure 2. A high level of ﬁbrin does not protect against pneumonic plague in
naı¨ve mice
C57BL/6 mice were i.n. inoculated with 2105 CFU KIM D27 and 2106CFU KIM
D27/pLpxL. On days 1, 2, 3, 4, 7, 10 after inoculation, the mice were sacriﬁced, and
the deposition in the livers was observed. (A) Initially, the ﬁbrin levels in the mice
infected with KIM D27/pLpxL were higher, and the levels were lower at day 3 than
the ﬁbrin levels in the mice infected with KIM D27. C57BL/6 mice were i.n.
inoculated with 2105 CFU KIM D27 and 2106 CFU KIMD27-pLpxL and monitored
for survival. We determined that the mice infected with a lower dose of KIM D27 (B)
could succumb to bacterial infection signiﬁcantly earlier than the mice infected
with higher dose of KIMD27-pLpxL (p<0.0001, 10 mice per group). Results similar
to those shown in Figure 1 were observed in two independent experiments. The
survival data were analyzed by a log rank test. The data were analyzed using
Student’s t-test.
Figure 3. Coagulation factor responses against lipopolysaccharide deploy ﬁbrin formation through MyD88
(A) Wild type C57BL/6 mice and MyD88-deﬁcient mice were i.p. inoculated with 50ug LPS (hexa-acylated lipid A, low dose). Twenty-four hours later, the hepatic ﬁbrin levels
were measured quantitatively. We detected a higher level of transient ﬁbrin deposition within liver tissue in wild type C57BL/6 mice than in MyD88 KO mice (A, p=0.002).
Fibrin levels are determined by PTase activity, PCase activity and PA activity. We assessed PA, PCase and PTase activities in liver tissue. We found that MyD88 gene deﬁciency
does not affect infection-stimulated hepatic PTase activity (E); however, it increases infection-stimulated hepatic PA activity (C, p=0.004) and PCase activity (D, p=0.003).
PTase activity, PCase activity and PA activity are regulated by a number of factors, such as TF, TM, TAFI, uPA, tPA and PAI-1. The hepatic mRNA levels showed that MyD88
deﬁciency had no effect on most of the factors; however, it decreased PAI-1 expression (F, p<0.00001), TAFI expression (G, p=0.002) and TM expression (H, p=0.017). Results
similar to those shown in Figure 3 were observed in two independent experiments. Wild type C57BL/6 mice were i.p. inoculated with 50 mg LPS (hexa-acylated lipid A) at the
identical time, and the hepatic ﬁbrin levels were measured. In comparison with the mice injected with 50 mg tetra-acylated LPS, the ﬁbrin level is obviously lower (B, p=0.03).
The data were analyzed using Student’s t-test.
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Figure 4. Hexa-acylated LPS-lipid A regulates coagulation factors to deposit the
appropriate level of ﬁbrin for protection
We designed a graph to interpret this regulation. Hexa-acylated LPS-lipid A is a
strong activator of human cells; however, tetra-acylated LPS-lipid A has lower
stimulatory activity. Hexa-acylated LPS-lipid A binds to Toll like receptor 4 (TLR4)
and stimulates the expression of coagulation factors through MyD88. Hexa-
acylated LPS-lipid A stimulates PAI1 expression, which can inhibit PA activity, and
stimulates TAFI and TM expression, which can inhibit PCase activity. PA activity and
PCase activity can regulate ﬁbrin deposition. Because tetra-acylated LPS-lipid A has
lower stimulatory activity, its binding to TLR4 cannot regulate PAI1, TAFI and TM
expression, which induce very high levels of ﬁbrin deposition. Hexa-acylated LPS-
lipid A and tetra-acylated LPS-lipid A could activate TF directly or indirectly, which
indicated that PTase is not inﬂuenced by the lipid A structure.
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factors to deposit the appropriate level of hepatic ﬁbrin. The lipid A
structure in LPS is the only difference between KIM D27 and KIMFigure 5. A high level of ﬁbrin blocks phagocyte migration to infection sites
C57BL/6 mice were treated with various concentrations of Coumadin (2 mg/L, 0.5 mg/L) b
days after the initiation of infections. Representative paraformaldehyde-ﬁxed samples w
mice treated higher concentration Coumadin (A, 2 mg/L) In comparison with mice trea
Results similar to those shown in Figure 5 were observed in two independent experimD27-pLpxL at the host temperature. We injected wild type C57BL/6
and MyD88 gene deﬁcient (MyD88 KO) mice intraperitoneally
with 50 mg LPS (Sigma-Aldrich, E.coli 0111:B4), which possesses
hexa-acylated lipid A. The ﬁbrin levels in the liver tissue samples
were measured quantitatively by Western blotting as previously
described.10 We detected a higher level of transient ﬁbrin
deposition in the liver tissue in the wild type C57BL/6 mice than
in the MyD88 KO mice (Figure 3A). Fibrin formation is regulated by
PTase activity, PCase activity and PA activity; therefore, assays for
PTase, PCase and PA activities were performed in situ. We found
MyD88 gene deﬁciency does not affect infection-stimulated
hepatic PTase activity (Figure 3E); however, it increases infec-
tion-stimulated hepatic PCase activity (Figure 3D) and PA activity
(Figure 3A). The activities of PTase, PCase and PA are regulated by a
number of factors, such as TF, TM, TAFI and PAI-1 as described
above; we evaluated their mRNA levels in liver tissue. MyD88-
deﬁciency decreases TM expression (Figure 3H), PAI-1 expression
(Figure 3F) and TAFI expression (Figure 3G); it does not inﬂuence
the expressions of TF. These results were delineated by one graph
(Figure 4).
3.3. High level of ﬁbrin blocks phagocyte migration
The vaccine candidate, KIM D27-pLpxL, regulates the ﬁbrin
formation by lipid A. We hypothesize that although ﬁbrin performs
critical protective roles during infections, a high level of ﬁbrin
stops the migration of phagocytes. C57BL/6 mice were treated with
various concentrations of Coumadin (2 mg/L, 0.5 mg/L) before
infection with 2106CFU KIM D27/pLpxL, and hepatic tissue was
collected four days after the initiation of infections. Tissue samples
were stained with hematoxylin and eosin. In comparison with
mice treated with lower concentration Coumadin (Figure 5B), we
found more phagocytes in pathological inﬁltration in the mice
treated higher concentration Coumadin (2 mg/L) (Figure 5A).
4. Discussion
It appears contradictory that restricting bacteria dissemination
is the only protective mechanism of ﬁbrin in pneumonic plague. A
high level of ﬁbrin formation could be detected in wild-type mice
infected with KIM D27; however, ﬁbrin did not show signs of
protecting mice in this study. We hypothesized that ﬁbrin
conferred protection during pneumonic plague only when mice
deposited the appropriate level of ﬁbrin. Coumadin is an orallyefore infection with 2106CFU KIM D27/pLpxL, and hepatic tissue was collected four
ere stained with hematoxylin and eosin (200x). More phagocytes were found in the
ted with lower concentration Coumadin (0.5 mg/L) (B, p<0.01, 5 mice per group).
ents.
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anticoagulation. The mice treated with Coumadin possess a
normal level of circulating ﬁbrinogen; however, they generate
less ﬁbrin. Here, we used different doses of Coumadin to control
the ﬁbrin deposition levels. C57BL/6 mice were treated with
different doses of Coumadin in drinking water and were infected
with 2105 CFU KIM D27, and were then monitored for survival.
Mice treated with the highest Coumadin dose and mice treated
with no Coumadin succumbed to infection earlier than the mice
treated with a moderate dose of Coumadin. We detected moderate
ﬁbrin levels in mice treated with 0.5 mg/L Coumadin. To conﬁrm
this result, the modiﬁed bacteria, KIM D27/pLpxL, which produces
hexa-acylated LPS-lipid A was used in this study. Sara W
Montminy et al modiﬁed Y. pestis by introducing a plasmid
encoding acyltransferase.23 A modiﬁed bacteria strain could
produce hexa-acylated LPS-lipid A, which binds to TLR4 and
stimulates innate immune responses strongly through MyD88.
This modiﬁcation provides an excellent method of constructing a
new bacteria strain from KIM D27, which could be used to address
our hypothesis. Mice died when injected with a lower dose of KIM
D27, whereas mice injected with a higher dose of KIM D27/pLpxL
survived. We hypothesize that KIM D27/pLpxL could stimulate an
innate immune response and that KIM D27 could avoid innate
immunity. Additionally, we found the ﬁbrin levels were entirely
different between these two bacterial strains. KIM D27 bacteria
deposit very high levels of ﬁbrin during infection, and KIM D27/
pLpxL bacteria deposit moderate levels of ﬁbrin in liver tissues.
These data demonstrate our prediction that only the appropriate
level of ﬁbrin confers protection during infections.
Next, we investigated the detailed mechanism. A remarkable
interplay between bacteria and coagulation has been shown
during the last few decades. Additionally, our data suggest that
bacterial components regulate coagulation through MyD88 when
they regulate an innate immune response during infections. We
used lipopolysaccharide (hexa-acylated lipid A), one main viru-
lence component of gram-negative bacteria to address our
hypothesis. Wild type C57BL/6 and MyD88 gene-deﬁcient
(MyD88 KO) mice were intraperitoneally injected with LPS. We
detected a higher level of transient ﬁbrin deposition in the liver
tissue of the wild type C57BL/6 mice than in the MyD88 KO mice.
The mechanisms prompting ﬁbrin deposition have been studied
extensively. Exposure of tissue factor-bearing extravascular cells
activates coagulant pathways that culminate in the formation of a
PTase enzyme that converts prothrombin to thrombin. Thrombin
then cleaves ﬁbrinogen, prompting its polymerization and
deposition as ﬁbrin.27 Fibrin deposition is antagonized by
anticoagulant pathways and ﬁbrinolytic pathways. A principal
component of the anticoagulant response TM, a protein that binds
thrombin and modulates its proteolytic speciﬁcity28. The TM/
thrombin complex converts protein C (PC) to activated PC (APC), a
powerful suppressor of thrombin production. Additionally, this
TM-dependent PCase activates TAFI, an enzyme that cleaves
terminal lysines from ﬁbrin, thereby suppressing its degradation
by ﬁbrinolytic enzymes.29 PCase activity simultaneously sup-
presses further ﬁbrin formation, via activation of PC, and stabilizes
ﬁbrin deposits, via activation of TAFI. The primary mediator of
ﬁbrinolysis is plasmin, which is formed upon partial proteolysis of
plasminogen by PA.30Mammals produce two major PA, tissue-type
PA (t-PA) and urokinase-type PA (u-PA), and their activities are
antagonized by PAI1. Thus, the level of ﬁbrin deposition reﬂects a
balance of highly regulated hemostasis-related pathways in which
PTase, PCase and PA activities play major roles. Assays of PTase,
PCase and PA activities were performed in situ.25 We found that
MyD88 gene deﬁciency does not affect infection-stimulated
hepatic PTase activity; however, it increases infection-stimulated
hepatic PCase activity and PA activity. The activities of PTase, PCaseand PA are regulated by a number of factors such as TF, TM, TAFI
and PAI-1, as described above, and we evaluated their mRNA levels
in liver tissue. MyD88-deﬁciency decreases the expression of TM,
PAI-1 and TAFI; it does not inﬂuence the expression of TF. These
data suggest that coagulation factor responses against hexa-
acylated lipid A LPS deploy ﬁbrin formation through MyD88.
MyD88 deﬁciency suppresses infection-stimulated hepatic depo-
sition by promoting ﬁbrinolysis through PAI-1 and TAFI, promoting
anticoagulation through TAFI. MyD88-deﬁciency decreased the TM
expression slightly, and this phenomenon did not suppress PCase
activity. MyD88-deﬁciency does not affect TF exposure to initiate
coagulation.
We hypothesize that ﬁbrin performs critical protective roles
during infections, such as restricting bacterial dissemination,
recruiting neutrophils to clear microorganisms, and facilitating T
cell function. Additionally, we observed that a very high level of
ﬁbrin played a negative role during infection, in addition to that of
thrombosis. In our study, we found more phagocytes in
pathological inﬁltration in the mice treated higher concentration
Coumadin, suggesting that a very high level of ﬁbrin could stop the
migration of phagocytes.
Our data emphasize the essential function of ﬁbrin formation in
protection against pneumonic plague; we emphasize that only the
appropriate level of ﬁbrin confers protection. Scientists have
revealed a common ancestry of coagulation and the innate
immune system. Could we view the hemostatic pathways and
the pathways regulating immune response to infections and tissue
damage as entirely separate entities? The work in this study aimed
to augment our understanding of the roles for deploying ﬁbrin
formation by vaccine candidate components through MyD88,
which is typically considered to be a pathway for innate immune
responses. Some bacterial vaccine candidates could regulate
coagulation factors to deposit a moderate level of ﬁbrin for
protection.
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